Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.